These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15493002)

  • 21. Melanoma imaging with highly specific PET probes: ready for prime time?
    Minn H; Vihinen P
    J Nucl Med; 2011 Jan; 52(1):5-7. PubMed ID: 21149485
    [No Abstract]   [Full Text] [Related]  

  • 22. FDG PET in early stage cutaneous malignant melanoma.
    McIvor J; Siew T; Campbell A; McCarthy M
    J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanoma metastasis to the testis demonstrated with FDG PET/CT.
    Weng LJ; Schöder H
    Clin Nucl Med; 2004 Dec; 29(12):811-2. PubMed ID: 15545888
    [No Abstract]   [Full Text] [Related]  

  • 24. Positron emission tomography/computed tomography in melanoma.
    Bourgeois AC; Chang TT; Fish LM; Bradley YC
    Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma.
    Bastiaannet E; Hoekstra HJ; Hoekstra OS
    Methods Mol Biol; 2011; 727():123-39. PubMed ID: 21331932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
    Maubec E; Lumbroso J; Masson F; Suciu V; Kolb F; Mamelle G; Cavalcanti A; Boitier F; Spatz A; Aupérin A; Leboulleux S; Avril MF
    Melanoma Res; 2007 Jun; 17(3):147-54. PubMed ID: 17505260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of the literature for whole-body FDG PET in the management of patients with melanoma.
    Schwimmer J; Essner R; Patel A; Jahan SA; Shepherd JE; Park K; Phelps ME; Czernin J; Gambhir SS
    Q J Nucl Med; 2000 Jun; 44(2):153-67. PubMed ID: 10967625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. F-18 fluorodeoxyglucose positron emission tomography/computed tomography in conjunctival melanoma with recurrence.
    Jain A; John AR; Kishore B; Vishnoi MG; Pandit AG; Sharma A; Jaimini A; Jain M; Singh A
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S240-S242. PubMed ID: 33380688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: a pilot study.
    Prakoso E; Fulham M; Thompson JF; Selby WS
    Gastrointest Endosc; 2011 Apr; 73(4):750-6. PubMed ID: 21288518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
    Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
    J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients.
    Bastiaannet E; Oyen WJ; Meijer S; Hoekstra OS; Wobbes T; Jager PL; Hoekstra HJ
    Br J Surg; 2006 Feb; 93(2):243-9. PubMed ID: 16323165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advantages and limitations of FDG PET in the follow-up of breast cancer.
    Lind P; Igerc I; Beyer T; Reinprecht P; Hausegger K
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S125-34. PubMed ID: 15085295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.
    Macfarlane DJ; Sondak V; Johnson T; Wahl RL
    J Clin Oncol; 1998 May; 16(5):1770-6. PubMed ID: 9586890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
    Twycross SH; Burger H; Holness J
    S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG PET in the management of endometrial cancer.
    Chao A; Chang TC; Ng KK; Hsueh S; Huang HJ; Chou HH; Tsai CS; Yen TC; Wu TI; Lai CH
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):36-44. PubMed ID: 16167154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography for staging and management of malignant melanoma.
    Prichard RS; Hill AD; Skehan SJ; O'Higgins NJ
    Br J Surg; 2002 Apr; 89(4):389-96. PubMed ID: 11952577
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
    Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET and PET-CT for evaluation of colorectal carcinoma.
    Delbeke D; Martin WH
    Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.